Company intelligence / Profile preview

Ora Bio Ltd

Ownership: Private
Development stage: Commercial

Overview

Ora Bio Ltd focuses on the repositioning of existing drugs for new therapeutic uses. Its two main products are currently in Phase II clinical trials: ORA101 for non-small cell lung cancer and ORA102 for age-related macular degeneration. The company leverages its expertise to accelerate development timelines by repurposing known compounds, potentially reducing risk compared to novel drug discovery approaches[4].

Therapeutic areas: OncologyOphthalmology
Modalities: Small molecules (implied by drug repositioning focus)
Industry: Biotech

Drug pipeline

1 asset

ORA102

Beyond the preview

Go deeper on Ora Bio Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ora Bio Ltd.

Explore the full profile